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We have studied four organic acids of similar structure to further understand the basis of their developmental toxicity. Valproic acid (2-propyl
pentanoic acid), ethylhexanoic acid, and octanoic acid are isomeric C8 organic acids but their teratologic potency varied widely. Valproic acid induced
a moderate to severe teratologic outcome after a single oral administration of 6.25 mmoles/kg on day 12 of rat pregnancy. Twice as much
ethylhexanoic acid (12.5 mmoles/kg) induced a less severe response. Octanoic acid was nonteratogenic even at the very high dose of 18.75
mmoles/kg. This latter result is undoubtedly due to poor intestinal absorption of octanoic acid, as the maternal plasma levels never reached half of
those measured for valproic acid and ethylhexanoic acid. Moreover, only a tiny fraction of that in maternal plasma was actually transferred into the
embryo. On the other hand, the peak concentration and duration of exposure to valproic acid and ethylhexanoic acid were very similar despite a
more severe teratologic outcome following valproic acid, which indicated higher intrinsic activity of this latter agent. A fourth agent, methylhexanoic
acid, was also studied and had no teratogenic effects when given at 14.1 mmoles/kg. Pharmacokinetic studies of this agent revealed higher peak
concentrations in maternal plasma and embryo than valproic acid or ethylhexanoic acid, but the duration of exposure was shorter. We conclude that
pharmacokinetic parameters can be important determinants of teratologic outcome and thereby help explain differing potencies of structurally
similar chemicals. - Environ Health Perspect 102(Suppl 1 1):97-101 (1994)
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Introduction
Some years ago we indicated that most
well-documented human teratogens are
weak acids and speculated that, in part,
this might be due to accumulation of
acidic chemicals in the alkaline milieu of
the early postimplantation embryo (1). In
our present work, we have examined the
teratogenic activity and transplacental dis-
tribution of three isomeric C8 organic
acids, valproic acid (VPA, 2-propyl pen-
tanoic acid), 2-ethyl hexanoic acid
(EHXA), and octanoic acid (OA). The
choice of these agents came from Ritter et
al.'s study (2) showing that VPA was about
twice as potent as EHXA in regard to
developmental toxicity under identical
dosage conditions in pregnant rats.
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Malformations were mainly of the limb,
tail, kidney, or cardiovascular system. The
similar chemical structure and the similar
malformation profile prompted these
authors to speculate that these agents may
work via the same mechanism.
A potential means by which the differ-
ing potencies of EHXA and VPA might
arise is through some aspect ofpharmacoki-
netics. It is our belief that both agents are
teratogenic through a direct action of the
parent compound on the embryo. Thus the
transplacental distribution of each agent
will be a major determinant of teratogenic
potency.
Herein we examined the transplacental
pharmacokinetics ofVPA and EHXA after
oral dosing on day 12 of rat gestation.
Because the Wistar strain of rat used by
Ritter et al. (2) could no longer be
obtained, the present study used Sprague-
Dawley rats, and a new teratology study
was conducted to verify the different ter-
atogenic potency ofEHXA versus VPA in
this rat stock. The straight chain C8 iso-
mer, octanoic acid, was included in the study
because other reports indicate a limited
embryotoxicity associated with this agent
in vivo (3) or in vitro (4).
As the study began, it was decided to
add another agent, methylhexanoic acid
(MHXA). This agent with one less carbon
than the other organic acids was chosen
because it was reported to possess very low
embryotoxicity (4) but does have similar
structure to the branched chain acids, VPA
and EHXA. Our goal was to examine the
association of embryotoxic response with
transplacental pharmacokinetic distribu-
tion as a potential explanation for the dif-
fering teratologic potency of these
chemically similar agents.
Materials and Methods
Studies were conducted with pregnant
Sprague-Dawley rats purchased time-
mated from Charles River (Portage, MI).
The animals arrived at our laboratory on
day 6 or 7 of pregnancy, allowing 5 to 6
days for acclimation prior to toxicant
administration. Upon arrival, the females
were housed in small groups in hanging
wire cages in rooms maintained at a con-
stant temperature (22 ± 1°C), relative
humidity (50± 5%), under a controlled 12-
hr light-dark cycle and fed Purina Rodent
Laboratory Chow and water adlibitum.
EHXA and MHXA were purchased
from Aldrich (Milwaukee, WI). VPA and
OA were obtained from Sigma Chemical
Company (St. Louis, MO). All four agents
were administered undiluted by oral gavage
on the morning ofday 12 of rat gestation
(day 0 =morning offindingvaginal plug).
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Table 1. Embryotoxicity of C7 and C8 organic acids administered orallyto Sprague-Dawley rats on day 12 of gestation.
Agent Dose, mmoles/kg No. surv. females/no. treated No. impl. sites No. res. or dead (%) No. surv. malf. (%) Mean fetal wt., M/F
Control 0 10/10 108 6(6) 1(1) 3.90/3.71
VPA 4.69 4/4 56 10(18) 5(11) 3.39/3.03
VPA 6.25 12/13 115 33 (29) 50 (61) 2.65/2.66
EHXA 12.5 9/9 113 16 (14) 36 (37) 2.82/2.68
EHXA 15.625 7/7 78 47(60) 31(100) 2.06/1.93
MHXA 14.1 7/10 81 2 (2) 0 (0) 3.29/3.46
OA 18.75 11/12 131 10(9) 4(3) 3.48/3.23
TeratologyStudies
On day 20 ofgestation, the rats were killed
by chloroform overdose. The uterine horns
were exposed through incision of the ven-
tral abdominal wall and examined for
placement of fetuses and counting of
resorption sites. The fetuses were removed
from the uterus, examined grossly for the
occurrence of malformations, sexed,
weighed, and then placed in Bouin's fluid
(2/3) or in alcohol (1/3). Those in Bouin's
fluid were subsequently examined by razor
blade sectioning (5); those in alcohol were
double stained for examination ofcartilage
and bone (6).
Transplacental Pharmacokinetics
At various intervals after dosing (0.25, 0.5,
1, 2, 4, 8, and 24 hr), pregnant rats were
anesthetized with ether and the uterine
horns were exposed through a ventral
abdominal incision. Three to four embryos
were dissected free of their surrounding
membranes, dried ofexcess fluid with filter
paper wedges, and placed in a preweighed
Eppendorf tube and weighed on a five
place electronic balance. Another three to
four embryos were removed from the
uterus with the membranes intact, and the
exocoelomic fluid was removed by punc-
ture ofthe membranes with a micropipette.
This fluid was expelled into a preweighed
Eppendorf tube for determination of toxi-
cant concentration. The yolk sacs from
these preparations were then collected and
placed in a preweighed Eppendorf tube.
Next, a sample ofmaternal skeletal muscle
was taken from the anterior thigh and
placed in a preweighed Eppendorf tube.
Finally, a sample 6f maternal blood was
withdrawn in a heparinized syringe from
the abdominal aorta. This sample was cen-
trifuged and the plasma removed to a
preweighed Eppendorf tube. All samples
were then frozen at -80°C until shipment
on dry ice to Berlin, where the content of
organic acid was measured by gas chro-
matography and mass spectrometry as
described in detail by Fisher et al. (7). One
or two remaining embryos were then exam-
ined under a dissecting microscope and the
number ofsomites was counted as an indi-
cator ofactual embryonic age.
Results and Discussion
The developmental toxicity associated with
administration ofa C7 or C8 organic acid
on day 12 ofrat gestation is summarized in
Table 1. MHXA and OA were essentially
devoid ofembryotoxic effects except for a
slight reduction offetal weight, most likely
attributable to the severe maternal toxicity
that accompanied the administration of
these agents. This outcome was not unex-
pected because Nau et al. (3) showed that
OA did not induce exencephaly when
given to pregnant mice, and Brown et al.
(4) showed that neither agent had any seri-
ous effect on rat embryos in culture at a
concentration of 1 mM. VPA and EHXA
were toxic to the 12-day rat embryo, caus-
ing increased death and malformation and
a reduction of fetal weight. These results
are also not surprising and agree reasonably
well with an earlier report (2) from work
done in Wistar rats. Both agents cause a
similar spectrum of malformations when
administered on day 12 ofrat gestation and
involve mainly the cardiovascular system
and the appendicular skeleton. This simi-
larity suggests that these two agents act by
the same mechanism to divert embryonic
development. In Table 2, which lists the
most frequently occurring malformations
there are some interesting differences that
are dependent on the agent or strain ofrat.
With regard to cardiovascular malforma-
tions, VPA generally seemed to be more
potent than EHXA and this was especially
true with regard to alterations ofthe ductus
arteriosus. In the present study utilizing
Table 2. Specific malformations induced by oral treatment with valproic acid or ethylexanoic acid on day 12 of rat
gestation.
Externally examined
Visceral exam
Skeletal exam
Cardiovascular
Levocardia
IV septal defect
Truncus communis
Double-outlet RV
Ductus arteriosusb
Others
Axial skeleton
Tail
Appendicular skeleton
Ectrodactyly, fl
Bowed radii
Bowed ulnae
Polydactyly
Bowed fibulae
Urogenital
Hydronephrosis
Sprague-Dawley
VPA
6.25 mmoles/kg
115
55
27
17/55
2/55
1/155
15/55
11/55
35/55C
39/115
21/115
10/27
4/27
3/115
9/27
7/55
Sprague-Dawley
EHXA
12.5 mmoles/kg
97
65
32
3/65
1/65
1/65
0/65
1/65
2/65d
2/97
17/97
4/32
0/32
3/97
1/32
6/65
Wistara
VPA
6.25 mmoles/kg
104
72
32
15/72
4/72
7/72
6/72
10/72
5/72e
18/104
1/104
3/32
1/32
0/104
0/32
15/72
Wistara
EHXA
12.5 mmoles/kg
115
79
36
5/79
2/79
0/79
4/79
2/79
8/79f
24/115
31/115
26/36
11/36
6/115
9/36
18/79
aData from Ritter et al. (2). Includes short, missing, right-sided, dilated, or stenotic ductus arteriosus. Clncludes
five carotid agenesis, three dilated pulmonary artery, four right-side descending aorta, three pulmonary stenosis,
two constricted aortic arch, two right-sided aortic arch, two double aortic arch, two ringed aortic arch, two dilated
aortic arch, two misplaced carotid, eight valvula communis. dIncludes one carotid agenesis, one valvula commu-
nis. elncludes two right-sided aortic arch, one carotid agenesis, one dilated pulmonary, one dilated aortic arch.
fIncludes three ringed aorta, one right-sided aortic arch, one carotid agenesis, one pulmonary stenosis, one double
aortic arch, one dilated aortic arch.
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Table 3. Litter-specific developmental toxicity ofVPA and EHXA given on day 12 of rat gestation.a
VPA EHXA
Malformations/ Malformations/
Litter no. Total Res. Malf. malf. surv. Total Res. Malf. malf. surv.
1 100 100 0 62 31 31 1.5 ± 1.0
2 100 13 87 13.2±3.1 36 14 21 3.7±4.6
3 80 20 60 6.3 ± 9.2 50 43 7 1.0 ±0
4 0 0 0 93 0 93 3.0± 1.5
5 100 71 29 7.0 ± 7.5 58 25 33 2.3 ± 1.5
6 100 75 25 3.3 ± 1.2 46 0 46 1.7 ± 1.2
7 30 0 30 1.0 ±0 67 33 33 2.0 ±0
8 100 0 100 2.2±1.8 7 0 7 1.0±0
9 100 67 33 8.5±0.7 13 0 13 1.0±0
10 43 7 36 1.0±0
11 45 9 36 1.5±0.6 -
12 100 30 70 12.9±4.3
aPercentage of implation sites affected by death or malfo
Sprague-Dawley rats, limb malformations
were slightly more prevalent after VPA
treatment. However, in the earlier study
(2), EHXA clearly was more potent than
VPA in this regard. Most often the limb
malformations were bilaterally expressed
and preferentially affected preaxial struc-
tures in the forelimb (bowed radii, ectro-
dactyly ofdigit 2), but postaxial hind limb
structures (bowed fibula) were seen in
Sprague-Dawley rats given VPA and in
Wistar rats given EHXA. These findings
have no credible explanations.
An interesting aspect of these results is
the variation in frequency and severity of
embryotoxic outcome between litters, espe-
cially in response to VPA (Table 3). Thus
we had 7/12 litters in which all implanta-
tion sites were affected and one that had
no embryotoxic effect. Furthermore, there
was great disparity in the number of mal-
formations in an individual fetus that was
strongly correlated by litter. Thus, in two
litters the malformed fetuses averaged
approximately 13 malformations/individ-
ual (range = 8-22). In other litters, each
individual had only one or two malforma-
tions. Both types of variation, frequency
and severity of embryotoxic effect, were
greatly reduced in litters exposed to
EHXA. This same interlitter variability was
evident in the previous study in Wistar rats
(2).
This same trend oflitter-specific effect
is also evident in the fetal weight data. The
standard deviation is less than 10% ofthe
mean fetal weight for control animals but
3-fold higher for VPA-exposed fetuses
(Table 4). Values for EHXA, MHXA, and
OA were intermediate between controls
and VPA-exposed fetuses, but EHXA
fetuses had the lowest variation of any of
the treated embryos.
This great variation in developmental
toxicity outcome between litters was also
evident in the pharmacokinetic results in
which the standard deviation from the
mean of maternal plasma or embryo
homogenate concentration was usually
greater than 50%. We believe this variation
ofxenobiotic concentration between litters
is real and based on three facts. First, when
the same sample was rerun, the variation
was within reliable limits. For example, six
samples ofembryos exposed to EHXA were
reanalyzed two or three times and the stan-
dard deviation of the mean was less than
10% in all cases but one, where it was
13.3%. Similarly, in 12 samples ofembryo
homogenate exposed to MHXA variability
was usually a little higher, approximately
20% ofthe mean. A second line ofreason-
ing to uphold the idea oflitter variability
was the consistency ofxenobiotic concen-
tration in samples from the same animal.
Thus, if maternal plasma contains a high
concentration of xenobiotic, then other
samples from the same litter (e.g., embryo
homogenate, yolk sac, exocoelomic fluid or
maternal skeletal muscle) were likewise
high; conversely, if maternal plasma was
low, then these other samples were corre-
spondingly low. The third factor indicating
the validity of these variable results is
related to the physical property of these
agents as weak acids, which influences the
extent oftheir distribution within a com-
partment based on pH. In Table 5 the free
concentration ofVPA in maternal plasma 4
hr after treatment shows great variability in
the four mothers (29-530 mg/ml), yet the
ratio ofVPA in four compartments ofvary-
ing pH (8) is very consistent. This indicates
that the variation among individual animals
is real. Moreover, this variation ofxenobi-
otic concentration from animal to animal is
similar to the large interlitter variation of
embryotoxic response and presumably is
responsible for this litter effect. The basis of
this pharmacokinetic difference (and pre-
sumably the dependent embryotoxic out-
come) is unknown. The rats were not fasted
overnight prior to early morning adminis-
tration. Thus, varying amounts of gastric
contents could have contributed to differ-
ence from rat to rat in the widely fluctuat-
ing maternal plasma concentrations.
The pharmacokinetic results provide
additional insights into the teratologic
potency associated with these structurally
similar organic acids. Figure 1 depicts the
concentration ofeach of the four acids in
Table 4.Weight of day 20 rat fetuses exposed to an organic acid on day 12 of pregnancy.
Control VPA EXHA MHXA OA
Litter no. Male Female Male Female Male Female Male Female Male Female
1 3.6 3.4 1.5 1.4 2.5 2.2 2.4 2.3 3.8 3.7
2 4.2 3.9 3.0 2.6 2.6 2.3 3.8 3.6 3.8 3.5
3 4.0 3.7 3.2 3.0 3.6 3.5 3.7 3.7 2.5 2.2
4. 4.0 3.9 2.5 2.4 2.7 2.4 3.9 3.9 3.7 3.3
5 4.0 3.8 2.5 2.2 2.6 2.5 3.9 3.9 3.5 3.2
6. 3.9 3.7 3.2 3.1 2.8 2.8 2.8 2.7 3.3 3.2
7 3.5 3.4 3.3 3.1 2.4 3.7 3.7 3.8 3.7
8 4.3 4.1 2.3 1.9 3.0 2.8 4.1 3.9
9 4.5 4.2 3.4 3.1 3.0 3.1 2.2 2.0
10 3.9 3.6 3.2 3.1
3.99 ± 0.30 3.77 ± 0.27 2.81 ± 0.60 2.59 ± 0.60 2.80 ± 0.36 2.70 ± 0.44 3.46 ± 0.60 3.41 ± 0.65 3.19 ± 0.66
% variability 7.5 7.2 21.3 23.2 12.9 16.3 17.3 18.5 19.1 20.7
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Table 5. Ratio of VPA in embryonic, extraembryonic, and maternal compartments compared to the free concentra-
tion in maternal plasma 4 hr after intubation.
Plasma- Embryo Yolk Excocoelomic Maternal
free, homogenate, sac, fluid, muscle,
pg/ml plasma-free plasma-free plasma-free plasma-free
530 1.06 0.83 1.25 0.38
29 1.10 1.10 1.45 0.38
296 1.09 1.05 1.56 0.48
120 0.98 0.87 1.16 0.37
244 ± 221 1.06 ± 0.05 0.96 ± 0.13 1.36 ± 0.18 0.40 ± 0.05
% variation 91 5 14 13 13
VPA EHXA
Table 6. Relative teratogenic sensitivity or resistance to
fourorganic acids.
Teratogenic Sensitivity
Agent in vivo in vitro Explanation
VPA ++++ ++++ High intrinsic activity
High embryonic exposure
EHXA ++ ++ Moderate intrinsic activity
High embryonic exposure
MHXA + Low intrinsic activity
High embryonic exposure
OA + ? intrinsic activity
Low embryonic exposure
aResults extrapolated from Brown et al. (4) and Nau et
al. (9).
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Figure 1. Disposition offour organic acids in maternal plasma (-)-and embryo (o) on day 12 of rat pregnancy.
maternal plasma and embryo homogenate.
The basis of low embryotoxic potential of
OA becomes evident immediately. Very lit-
tle of the administered dose reaches the
maternal blood stream, and only a small
fraction of that is transferred into the
embryo. In contrast, MHXA, also of low
embryotoxic potential, reaches a very high
concentration in maternal plasma and
embryo although it is eliminated more
quickly than EHXA and VPA. Thus, the
chemical structure ofMHXA is sufficiently
different from VPA and EHXA so that the
cellular process disrupted by these terato-
gens is not susceptible to alteration by
MHXA.
The levels of EHXA and VPA in both
maternal plasma and embryo are roughly
equivalent, despite giving twice as much
EHXA to the maternal animal. This sug-
gests that VPA and EHXA are equipotent
within the embryo but that maternal
pharmacokinetic factors lead to a more
efficient uptake and transport ofVPA. This
conclusion is not borne out by study of
VPA and EHXA in rat whole embryo cul-
ture (4) where EHXA was less potent than
VPA. The embryonic concentration of
either agent was not determined in this
study so that pharmacokinetic factors such
as protein binding could lead to different
levels of teratogen in the embryo despite
identical concentration in the culture
medium (9).
Conclusion
The work presented here indicates that
pharmacokinetic characteristics ofa chemi-
cal agent will influence the associated devel-
opmental toxicity; however, intrinsic
activity ofeach agent is also an important
determinant ofteratologic outcome. Table
6 summarizes work done on the four
organic acids studied herein, and indica-
tions of pharmacokinetic and intrinsic
activity determinants of outcome are evi-
dent. MHXA distributes to the putative tar-
get site, the embryo, quite readily but is
nonteratogenic at a concentration which
VPA and EHXA induce severe develop-
mental toxicity. OA had very low potential
to induce developmental toxicity, which
was clearly due to a low concentration in
maternal plasma and very little placental
transfer, presumably due to protein binding
in maternal plasma (9). OA also possesses
low intrinsic activity as shown in rodent
whole embryo culture (4,9). It is surpris-
ingly more active than VPA in some non-
mammalian developmental systems (10).
Results from this work also indicate that
pharmacokinetic parameters can help
explain the varying teratologic response
within members ofthe same species. Highly
varying concentrations ofVPA were corre-
lated with a widely fluctuating teratologic
response. An experimental design combin-
ing pharmacokinetic analysis and
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teratologic examination in the same animal
would permit a more direct answer to the
basis of the so-called litter effect. This
approach has been successful in the expla-
nation ofimportant pharmacokinetic deter-
minants ofsalicylate teratogenicity (11) and
warrants consideration for further studies
with 'VPA and associated organic acids.
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